{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:48:32Z","timestamp":1791830912001,"version":"4.3.4"},"reference-count":113,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heat-shock proteins are upregulated in cancer and protect several client proteins from degradation. Therefore, they contribute to tumorigenesis and cancer metastasis by reducing apoptosis and enhancing cell survival and proliferation. These client proteins include the estrogen receptor (ER), epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), human epidermal growth factor receptor 2 (HER-2), and cytokine receptors. The diminution of the degradation of these client proteins activates different signaling pathways, such as the PI3K\/Akt\/NF-\u03baB, Raf\/MEK\/ERK, and JAK\/STAT3 pathways. These pathways contribute to hallmarks of cancer, such as self-sufficiency in growth signaling, an insensitivity to anti-growth signals, the evasion of apoptosis, persistent angiogenesis, tissue invasion and metastasis, and an unbounded capacity for replication. However, the inhibition of HSP90 activity by ganetespib is believed to be a promising strategy in the treatment of cancer because of its low adverse effects compared to other HSP90 inhibitors. Ganetespib is a potential cancer therapy that has shown promise in preclinical tests against various cancers, including lung cancer, prostate cancer, and leukemia. It has also shown strong activity toward breast cancer, non-small cell lung cancer, gastric cancer, and acute myeloid leukemia. Ganetespib has been found to cause apoptosis and growth arrest in these cancer cells, and it is being tested in phase II clinical trials as a first-line therapy for metastatic breast cancer. In this review, we will highlight the mechanism of action of ganetespib and its role in treating cancer based on recent studies.<\/jats:p>","DOI":"10.3390\/ijms24055014","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T04:29:58Z","timestamp":1678076998000},"page":"5014","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-6346","authenticated-orcid":false,"given":"Mahmoud E.","family":"Youssef","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8925","authenticated-orcid":false,"given":"Simona","family":"Cavalu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru Madalin","family":"Hasan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-7863","authenticated-orcid":false,"given":"Galal","family":"Yahya","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Abd-Eldayem","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-7851","authenticated-orcid":false,"given":"Sameh","family":"Saber","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e202005102","DOI":"10.1083\/jcb.202005102","article-title":"Stress granules display bistable dynamics modulated by Cdk","volume":"220","author":"Yahya","year":"2021","journal-title":"J. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/1751-7915.13904","article-title":"Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast","volume":"14","author":"Yahya","year":"2021","journal-title":"Microb. Biotechnol."},{"key":"ref_4","unstructured":"Wegele, H., M\u00fcller, L., and Buchner, J. (2004). Reviews of Physiology, Biochemistry and Pharmacology, Spinger."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nmeth.3556","article-title":"Inntags: Small self-structured epitopes for innocuous protein tagging","volume":"12","author":"Georgieva","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.molcel.2013.11.015","article-title":"A Whi7-anchored loop controls the G1 Cdk-cyclin complex at start","volume":"53","author":"Yahya","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e98724","DOI":"10.15252\/embj.201798724","article-title":"Cdc48\/p97 segregase is modulated by cyclin-dependent kinase to determine cyclin fate during G1 progression","volume":"37","author":"Parisi","year":"2018","journal-title":"EMBO J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1038\/sj.onc.1207114","article-title":"Heat-shock proteins as regulators of apoptosis","volume":"22","author":"Takayama","year":"2003","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt0998-833","article-title":"Stress-inducible responses and heat shock proteins: New pharmacologic targets for cytoprotection","volume":"16","author":"Morimoto","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12192-008-0068-7","article-title":"Guidelines for the nomenclature of the human heat shock proteins","volume":"14","author":"Kampinga","year":"2009","journal-title":"Cell Stress Chaperones"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chiricosta, L., Gugliandolo, A., Bramanti, P., and Mazzon, E. (2020). Could the heat shock proteins 70 family members exacerbate the immune response in multiple sclerosis? An in silico study. Genes, 11.","DOI":"10.3390\/genes11060615"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1021\/bi800639z","article-title":"Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families","volume":"47","author":"Vos","year":"2008","journal-title":"Biochemistry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1016\/j.febslet.2007.04.033","article-title":"Hsp27 (HspB1) and \u03b1B-crystallin (HspB5) as therapeutic targets","volume":"581","author":"Arrigo","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_14","unstructured":"Smith, H.L., Li, W., and Cheetham, M.E. (2015). Seminars in Cell & Developmental Biology, Elsevier."},{"key":"ref_15","unstructured":"Kubota, H. (2002). Vitamins & Hormones, Elsevier."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fmolb.2017.00055","article-title":"Bardet-Biedl syndrome as a chaperonopathy: Dissecting the major role of chaperonin-like BBS proteins (BBS6-BBS10-BBS12)","volume":"4","author":"Valverde","year":"2017","journal-title":"Front. Mol. Biosci."},{"key":"ref_17","unstructured":"Ito, S., and Nagata, K. (2017). Seminars in Cell & Developmental Biology, Elsevier."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Birbo, B., Madu, E.E., Madu, C.O., Jain, A., and Lu, Y. (2021). Role of HSP90 in Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910317"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9","article-title":"Molecular chaperones\u2014Cellular machines for protein folding","volume":"41","author":"Walter","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","article-title":"Molecular chaperones in protein folding and proteostasis","volume":"475","author":"Hartl","year":"2011","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hoter, A., El-Sabban, M.E., and Naim, H.Y. (2018). The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092560"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.apsb.2020.01.018","article-title":"Modulation of protein fate decision by small molecules: Targeting molecular chaperone machinery","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbamcr.2011.10.013","article-title":"GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum","volume":"1823","author":"Marzec","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Clarke, B.E., Kalmar, B., and Greensmith, L. (2022). Enhanced Expression of TRAP1 Protects Mitochondrial Function in Motor Neurons under Conditions of Oxidative Stress. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031789"},{"key":"ref_25","unstructured":"Cox, M.B., and Johnson, J.L. (2018). Chaperones: Methods and Protocols, Springer."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2319-4170.113230","article-title":"Structure, function and regulation of the hsp90 machinery","volume":"36","author":"Buchner","year":"2013","journal-title":"Biomed. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: Emerging mechanistic insights","volume":"11","author":"Taipale","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bbamcr.2011.11.009","article-title":"Hsp90 structure and function studied by NMR spectroscopy","volume":"1823","author":"Didenko","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"18473","DOI":"10.1074\/jbc.R800007200","article-title":"The Hsp90 chaperone machinery","volume":"283","author":"Wandinger","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1087057109360253","article-title":"Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the transcreener\u2122 ADP assay kit","volume":"15","author":"Rowlands","year":"2010","journal-title":"J. Biomol Screen."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/bm034093z","article-title":"Rotational Correlation Times of 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-yloxy Spin Label with Respect to Heme and Nonheme Proteins","volume":"4","author":"Cavalu","year":"2003","journal-title":"Biomacromolecules"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/cancers6021065","article-title":"The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer","volume":"6","author":"Hance","year":"2014","journal-title":"Cancers"},{"key":"ref_33","unstructured":"Bavisotto, C.C., Gammazza, A.M., Campanella, C., Bucchieri, F., and Cappello, F. (2022). Seminars in Cancer Biology, Elsevier."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mankovich, A.G., and Freeman, B.C. (2022). Regulation of Protein Transport Pathways by the Cytosolic Hsp90s. Biomolecules, 12.","DOI":"10.3390\/biom12081077"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbamcr.2011.09.009","article-title":"Secreted heat shock protein-90 (Hsp90) in wound healing and cancer","volume":"1823","author":"Li","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_36","unstructured":"Sahu, D. (2013). Characterization of a Fragment in Secreted Hsp90\u03b1 with Potential Therapeutic Benefits in Wound Healing and Cancer. [Ph.D. Thesis, University of Southern California]."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bcp.2008.10.019","article-title":"Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death","volume":"77","author":"Beck","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_38","unstructured":"Eguchi, T., Ono, K., Kawata, K., Okamoto, K., and Calderwood, S.K. (2019). Heat Shock Protein 90 in Human Diseases and Disorders, Springer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2013.08.004","article-title":"Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells","volume":"20","author":"Barrott","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s12272-015-0636-1","article-title":"Organelle-specific Hsp90 inhibitors","volume":"38","author":"Seo","year":"2015","journal-title":"Arch. Pharmacal Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.3390\/ijms140714240","article-title":"Intercellular communication by exosome-derived microRNAs in cancer","volume":"14","author":"Hannafon","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers7010238","article-title":"Extracellular molecules involved in cancer cell invasion","volume":"7","author":"Stivarou","year":"2015","journal-title":"Cancers"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kim, H., Seo, E.-H., Lee, S.-H., and Kim, B.-J. (2016). The telomerase-derived anticancer peptide vaccine GV1001 as an extracellular heat shock protein-mediated cell-penetrating peptide. Int. J. Mol. Sci., 17.","DOI":"10.20944\/preprints201611.0060.v1"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Marozzi, M., Parnigoni, A., Negri, A., Viola, M., Vigetti, D., Passi, A., Karousou, E., and Rizzi, F. (2021). Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment. Int. J. Mol Sci., 22.","DOI":"10.3390\/ijms22158102"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2009.07.010","article-title":"Geldanamycin and its anti-cancer activities","volume":"290","author":"Fukuyo","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cbdd.13486","article-title":"Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment","volume":"93","author":"Talaei","year":"2019","journal-title":"Chem. Biol Drug Des."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Prudhomme, M. (2013). Advances in Anti-Cancer Agents Medicinal Chemistry, Bentham Science Publishers. [1st ed.].","DOI":"10.2174\/97816080549301130101"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2009.10.026","article-title":"Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies","volume":"46","author":"Kummar","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19004","DOI":"10.1038\/srep19004","article-title":"CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells","volume":"6","author":"Xu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/or.2022.8443","article-title":"HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)","volume":"49","author":"Li","year":"2023","journal-title":"Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.xphs.2015.10.007","article-title":"Heat-shock protein 90-targeted nano anticancer therapy","volume":"105","author":"Rochani","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/ijc.31963","article-title":"Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma","volume":"144","author":"Augello","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_54","unstructured":"Yuno, A., Lee, M.-J., Lee, S., Tomita, Y., Rekhtman, D., Moore, B., and Trepel, J.B. (2018). Chaperones: Methods and Protocols, Springer."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Jhaveri","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1568009619666191202101330","article-title":"Old and new approaches to target the Hsp90 chaperone","volume":"20","author":"Sanchez","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS-116, a highly selective inhibitor of heat shock protein 90\u03b1 and \u03b2, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models","volume":"14","author":"Ohkubo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","first-page":"1849","article-title":"Ganetespib: Research and clinical development","volume":"8","author":"Jhaveri","year":"2015","journal-title":"OncoTargets Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer TherapyPreclinical Characterization of Ganetespib","volume":"11","author":"Ying","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Proia, D.A., Foley, K.P., Korbut, T., Sang, J., Smith, D., Bates, R.C., Liu, Y., Rosenberg, A.F., Zhou, D., and Koya, K. (2011). Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018552"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"C212","DOI":"10.1158\/1535-7163.TARG-11-C212","article-title":"Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats","volume":"10","author":"Zhou","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clbc.2013.12.012","article-title":"A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer","volume":"14","author":"Jhaveri","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00109-004-0549-9","article-title":"Targeting multiple signal transduction pathways through inhibition of Hsp90","volume":"82","author":"Zhang","year":"2004","journal-title":"J. Mol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138161213804143725","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1742-481X.2009.00622.x","article-title":"Epidermal growth factor in clinical practice\u2014A review of its biological actions, clinical indications and safety implications","volume":"6","year":"2009","journal-title":"Int. Wound J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/2278-330X.173164","article-title":"Human epidermal growth factor receptor 2\/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?","volume":"4","author":"Kumar","year":"2015","journal-title":"South Asian J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920207782446160","article-title":"The phosphoinositide 3-kinase pathway in human cancer: Genetic alterations and therapeutic implications","volume":"8","author":"Arcaro","year":"2007","journal-title":"Curr. Genom."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tirpe, A.A., Gulei, D., Ciortea, S.M., Crivii, C., and Berindan-Neagoe, I. (2019). Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246140"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10637-013-9971-6","article-title":"Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes","volume":"32","author":"Friedland","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1038\/cddis.2014.555","article-title":"Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-014-0329-6","article-title":"The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer","volume":"10","author":"Smith","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10456-013-9364-7","article-title":"Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1\u03b1 and STAT-3","volume":"16","author":"Ganji","year":"2013","journal-title":"Angiogenesis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00109-013-1102-5","article-title":"Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer","volume":"92","author":"Xiang","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_74","first-page":"967","article-title":"Ganetespib induces G2\/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling","volume":"51","author":"Lee","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2015.10.057","article-title":"Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib","volume":"52","author":"Nagaraju","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41388-017-0044-8","article-title":"HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome","volume":"37","author":"Amoreo","year":"2018","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biocel.2018.11.003","article-title":"Inhibition of HSP90\u03b2 by ganetespib blocks the microglial signalling of evoked pro-inflammatory responses to heat shock","volume":"106","author":"He","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"41294","DOI":"10.18632\/oncotarget.17180","article-title":"Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/ijc.24748","article-title":"Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt","volume":"125","author":"Bai","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Sindhu, R.K., Najda, A., Kaur, P., Shah, M., Singh, H., Kaur, P., Cavalu, S., Jaroszuk-Sieroci\u0144ska, M., and Rahman, M.H. (2021). Potentiality of Nanoenzymes for Cancer Treatment and Other Diseases: Current Status and Future Challenges. Materials, 14.","DOI":"10.3390\/ma14205965"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1078-0432.CCR-13-2166","article-title":"Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast CancerGanetespib Activity in Triple-Negative Breast Cancer","volume":"20","author":"Proia","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting oncogenic mutant p53 for cancer therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.cdd.4402301","article-title":"A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L\/TRAIL-induced apoptosis","volume":"15","author":"Weinmann","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2174\/156800909788166600","article-title":"Overcoming drug resistance by enhancing apoptosis of tumor cells","volume":"9","author":"Tortosa","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9980","DOI":"10.18632\/oncotarget.2484","article-title":"HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy","volume":"5","author":"Nagaraju","year":"2014","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/mol.107.043554","article-title":"The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway","volume":"73","author":"Javvadi","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"112898","DOI":"10.1016\/j.biopha.2022.112898","article-title":"Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies","volume":"149","author":"Rahman","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1016\/j.ijrobp.2012.07.1869","article-title":"Evaluating the HSP90 inhibitor ganetespib as a radiosensitizing agent in breast cancer models in vitro","volume":"84","author":"Corso","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10637-014-0095-4","article-title":"The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer","volume":"32","author":"He","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/15384047.2016.1156258","article-title":"Ganetespib radiosensitization for liver cancer therapy","volume":"17","author":"Chettiar","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_91","unstructured":"Clemente-Vicario, F. (2015). Biologic Activity of Selected Chemotherapeutic Agents and Small Molecule Inhibitors in Canine Lung Cancer Cell Lines. [Ph.D. Thesis, The Ohio State University]."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2012.1698","article-title":"Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression","volume":"42","author":"He","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","article-title":"The IL-6\/JAK\/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10637-011-9790-6","article-title":"Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models","volume":"30","author":"Proia","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2012-0039","article-title":"Inflammatory breast cancer: What we know and what we need to learn","volume":"17","author":"Yamauchi","year":"2012","journal-title":"Oncologist"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung CancerPhase II Trial of Ganetespib in NSCLC","volume":"19","author":"Socinski","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"A64","DOI":"10.1158\/1557-3125.METCA15-A64","article-title":"Abstract A64: Targeting HSP90 with ganetespib for targeted therapy of gastric cancer","volume":"14","author":"Liu","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.leukres.2015.03.016","article-title":"The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine","volume":"39","author":"Lazenby","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Goldman, J.W., Raju, R.N., Gordon, G.A., El-Hariry, I., Teofilivici, F., Vukovic, V.M., Bradley, R., Karol, M.D., Chen, Y., and Guo, W. (2013). A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-152"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/0008-5472.CAN-11-3600","article-title":"HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells17-AAG Abrogates Lymphoma Stem Cells","volume":"72","author":"Newman","year":"2012","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjh.12215","article-title":"The HSP 90 inhibitor NVP-AUY 922-AG inhibits the PI 3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells","volume":"161","author":"Walsby","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/COC.0000000000000377","article-title":"A Phase II study of Ganetespib as second- or third-line therapy for metastatic pancreatic cancer","volume":"41","author":"Cardin","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/jco.2012.30.4_suppl.467","article-title":"Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer","volume":"30","author":"Cercek","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1096\/fj.201700909R","article-title":"Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD)","volume":"32","author":"Nikonova","year":"2018","journal-title":"FASEB J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0003-4975(01)02787-4","article-title":"Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis","volume":"72","author":"Nguyen","year":"2001","journal-title":"Ann. Thorac. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2353\/jmoldx.2008.080105","article-title":"KRAS mutations: An old oncogene becomes a new predictive biomarker","volume":"10","author":"Riely","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-12-0615","article-title":"Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor GanetespibGanetespib Activity in KRAS-Mutant NSCLCs","volume":"11","author":"Acquaviva","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1535-7163.MCT-13-0481","article-title":"Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with GanetespibGanetespib Activity in Vemurafenib-Resistant Melanoma","volume":"13","author":"Acquaviva","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1158\/1078-0432.CCR-11-2138","article-title":"Molecular pathways: Targeting hsp90\u2014Who benefits and who does not","volume":"18","author":"Scaltriti","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s12272-012-1101-z","article-title":"Recent updates on the development of ganetespib as a Hsp90 inhibitor","volume":"35","author":"Choi","year":"2012","journal-title":"Arch. Pharmacal Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/labinvest.2010.150","article-title":"EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem\/progenitor cells in long-term monolayer cell culture","volume":"90","author":"Suzuki","year":"2010","journal-title":"Lab. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:38Z","timestamp":1760122118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":113,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24055014"],"URL":"https:\/\/doi.org\/10.3390\/ijms24055014","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}